STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration ...

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

Nucleosomes are barriers to RNA Polymerase II (Pol II) transcribing along gene bodies in eukaryotes. We found that a fragile “tailless nucleosome” could be generated to resolve the Pol II pausing ...

Tressie McMillan Cottom, Jessica Grose and Meher Ahmad on why plastic surgery and fillers no longer feel like a secret — or a ...

One of the most well-studied cellular responses is how they react during times of stress, such as when the temperature gets ...